ClinicalTrials.gg
RecruitingNCT05917405FLUCLORICUpdated Jan 30, 2026

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

A Phase 2 interventional study of Fludarabine and Busulfan in Acute Myeloid Leukemia in Remission, sponsored by Nantes University Hospital. Recruiting at 23 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Nantes University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 73 studies testing clofarabine in Leukemia, Myeloid, Acute — 4 open to participants now, 4 under way, none of them phase 3. Clofarabine · Leukemia, Myeloid, Acute.

Planned enrollment
5th of 72
302 · median 40
Started
2023
with 1 other
Phase 2
37 of 73
4 open now
Registered
72nd of 73
by date

Among the 73 studies testing clofarabine in Leukemia, Myeloid, Acute, this one is the 5th largest by planned enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2023, is one of 37 in phase 2, and was the 72nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 73 studies testing clofarabine in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About clofarabine

Clofarabine: first FDA approval 2004 (CLOLAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing clofarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Relapse remains the main cause of death in patients with myeloid malignancies, especially after an allotransplant. Using drugs with higher anti-leukemic activity as part of the conditioning regimen is one of the strategies to decrease relapse incidence in this population. Retrospective studies have shown that clofarabine can achieve impressive results compared to the use of fludarabine in acute myeloid leukemia (AML) as part of the conditioning regimen. Confirming such results in a prospective manner would definitely establish the CloB2A2 as a superior reduced-intensity conditioning (RIC) regimen compared to the FB2A2 for AML patients.302 AML patients (151 in each arm) in complete remission at transplant will be included with the main objective to demonstrate a significant better 2-year overall survival for CloB2A2 cases (70% vs 55%). A cost-utility analysis and a cost-effectiveness analysis will be also performed as well as an assessment of the quality of life after transplant. Clofarabine will be furnished to all centers. The duration of the study will be 5 years with 3 years of inclusion and 2 years of follow-up for each patient.

03

Conditions studied

  • Acute Myeloid Leukemia in Remission

Keywords

  • Acute Myeloid Leukemia
  • Clofarabine
  • fludarabine
  • reduced intensity conditioning regimen
  • allogeneic stem cells transplantation
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 years' old

  • De novo or secondary AML (according to ELN 2022 classification) in complete cytological remission at time of transplant (bone marrow blast count \< 5%) or MDS/LAM with bone marrow blast count ≤ 5%
  • Patients in first or therapy are allowed
  • Patient eligible to a RIC regimen : patients aged ≥ 60 year old or \<60 with co-morbidity(ies).
  • Patient with a related or an unrelated matched donor
  • Graft using only peripheral blood stem cells
  • Performance status 0 - 2
  • Who provide their written
  • Previous allograft allowed
  • Affiliated with French social security system or beneficiary from such system
  • Women must meet one of the following criteria at the time of inclusion:

    • use adequate measures as recommended by the CTFG (Recommendations related to contraception and pregnancy testing in clinical trials v1.1; includes injectable implants, dual hormone birth control pills, intrauterine devices, abstinence from sex, or a sterilized partner), and have a negative pregnancy test (urine or serum pregnancy test) prior to receiving the first dose of study drug;
    • or be (over 50 years of age with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal therapy)
    • or (if under 50 years of age) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal therapy and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels corresponding to post-menopausal levels
    • or have undergone irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented).
    • Contraception methods must be prescribed using effective contraceptive methods during treatment and within 6 months for women of childbearing age (WOCB) and 6 months for men in case they have sexual relations with WOCB after the last dose of Fludarabine/Clofarabine.

Exclusion criteria

Exclusion Criteria:

  • Pro-myelocytic leukemia
  • Patient eligible to a myeloablative conditioning regimen
  • Patient with haploidentical, mismatched unrelated donor or umbilical cord blood
  • Pregnant or breastfeeding woman or patient refusing mesures
  • positive
  • Active or C
  • \< 50%.
  • DLCOc \<40%
  • Uncontrolled infection
  • Uncontrolled haemolytic anaemia
  • \< 50 ml/min (evaluated by or CKDEPI).
  • Serum bilirubine > 30 mmol/l, Cytolysis > 5 the upper limit range
  • Previous or concurrent second except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Participation to another interventional study during the last month or expected participation to another interventional study during participation to the FLUCLORIC study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (estimated)

Study arms

  • Experimental
    Experimental: CloB2 arm

    * 30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2) * 3.2mg/kg/day IV busulfan once daily for 2 days (day -5 and -4) * ATG (Thymoglobuline®) 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1) Corticosteroids may be used in profilaxis

    Drug: Busulfan · Drug: ATG · Drug: Clofarabine

  • Active comparator
    Comparator: FB2A2 arm

    * 30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2) * 3.2 mg/kg/day IV busulfan once daily for 2 days (day -5 and -4) * ATG (Thymoglobuline®) 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)

    Drug: Fludarabine · Drug: Busulfan · Drug: ATG

Interventions

06

What researchers measure

Primary outcomes

  1. To compare 2-year OS between patients with AML in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT.

    OS is defined as the time from day 1 of conditioning to death or last follow-up for survivors.

    Time frame: 2 years

Secondary outcomes

  1. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT: Engraftment, primary and secondary graft failure

    * Engraftment: PNN \>500/mm3 + donor chimerism \>=5% (day +30/42) * Primary and secondary graft failure: donor chimerism \<5% at day +30/42 post-transplant (primary) or at distance of transplant after achieving engraftment (secondary)

    Time frame: day +30/42 and 2 years

  2. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT: Neutrophils and platelet recoveries

    * Neutrophils recovery: the first of three consecutive days with neutrophils ≥500/mm3 after aplasia from day 0 of the graft * Platelets recovery: the first of three consecutive days with platelets ≥20000/mm3 without transfusion after aplasia from day 0 of the graft

    Time frame: 2 years

  3. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT: 2-year DFS

    DFS: time from day1 of the conditioning to time without death or evidence of relapse or disease progression censored at the date of last follow-up.

    Time frame: 2 years

  4. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT:-2-year relapse incidence

    Relapse: any event related to progression or re-occurrence of the disease from day 1 of the conditioning.

    Time frame: 2 years

  5. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT:2-year NRM

    NRM: death from any cause without previous relapse or progression from day 1 of the conditioning

    Time frame: 2 years

  6. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT:Incidence of acute and chronic graft versus host disease (GVHD)

    * Acute GVHD: NIH criteria * Chronic GVHD: NIH criteria

    Time frame: Day 90 and 2 years

  7. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo-SCT:Incidence of GVHD free relapse free survival (GRFS)

    GRFS: alive with no previous grade III-IV acute GvHD, no moderate or severe chronic GvHD and no relapse from day 1 of the conditioning

    Time frame: 2 years

  8. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo SCT:Chimerism

    Chimerism: peripheral blood and CD3 T cells by molecular markers at days +30, +60, +90/100

    Time frame: days +30, +60, +90

  9. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo- SCT:Immune reconstitution

    Immune reconstitution: Immunophenotype of PB lymphocytes and EPP: CD4, CD8, B, NK, EPP at 3, 6 and 12 months

    Time frame: 3, 6 and 12 months

  10. To compare between AML patients in complete remission receiving either a CloB2A2 or a FB2A2 RIC regimen for allo- SCT: Minimal residual disease (MRD)

    Minimal residual disease (MRD): before transplant, at day +30 and day +90/100 by flow cytometry, molecular biology and NGS (if available) (ELN 2022 recommendation, Dohner et al Blood 2022)

    Time frame: days +30 and +90

  11. Comparison of infections after FB2A2 vs CloB2A2: bacterial, viral, parasitic and fungal

    Comparison of infections after FB2A2 vs CloB2A2: bacterial, viral, parasitic and fungal between day 0 and day+90/100

    Time frame: day+90

  12. Quality of life using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)

    Score of the QLQ-C30 questionnaire, including 30 questions assessing some aspects of the quality of life of cancer patients. The total score ranges from 0 to 100.

    Time frame: Days -7, +30, +90, +180, +360 and +720

  13. Quality of life using the and FACT-BMT (Functional Assessment of Cancer Therapy - Bone Marrow Transplant))

    Score of the FACT-BMT questionnaire, including 50 questions assessing some aspects of the quality of life of cancer patients. The total score ranges from 0 to 200.

    Time frame: Days -7, +30, +90, +180 and +360

  14. comparison of the cost of graft hospitalization between the 2 arms

    Graft hospitalization cost: Comparison between both groups in terms of length of stay (in days), use of antibiotics (type and length in days)

    Time frame: 2 years

  15. comparison of the cost of graft hospitalization between the 2 arms

    Graft hospitalization cost: Comparison between both groups in terms of blood products administered (numbers)

    Time frame: 2 years

  16. health benefit measurement in both treatment arms

    General Health State with Euroqol EQ-5D-5L questionnaire at Days -7, 30, 90, 180, 360 and 720; 5 answers are possible.

    Time frame: Days -7, +30, +90, +180, +360 and +720.

  17. Evaluation of economic efficiency of a CloB2A2 compared to a FB2A2 RIC regimen for allo-SCT, from a collective perspective (considering costs to the National Health Insurance system, hospital and patients)with a 24-month time horizon.

    Health Economic study: Incremental cost-utility ratio (ICUR, cost per quality-adjusted life year \[QALY\] gained) and incremental cost-effectiveness ratio (ICER, cost per life year gained), from a collective perspective and with a 24-month time horizon

    Time frame: 2 years

  18. Comparison of Overall survival (OS) between patients in first vs second line therapy and impact of clofarabine vs fludarabine in each sub-group.

    Comparison of time from D1 of conditioning to death or last follow-up for survivors

    Time frame: 2 years

  19. Comparison of DFS between patients in first vs second line therapy and impact of clofarabine vs fludarabine in each sub-group.

    Comparison of time from day1 of the conditioning to time without death or evidence of relapse or disease progression censored at the date of last follow-up.

    Time frame: 2 years

  20. Comparison of Overall survival (OS) between patients receiving a first vs a second allograft and impact of clofarabine vs fludarabine in each sub-group.

    Comparison of time from D1 of conditioning to death or last follow-up for survivors

    Time frame: 2 years

  21. Comparison of DFS between patients receiving a first vs a second allograft and impact of clofarabine vs fludarabine in each sub-group.

    Comparison of time from day1 of the conditioning to time without death or evidence of relapse or disease progression censored at the date of last follow-up.

    Time frame: 2 years

  22. Comparison of occurence of Veno-occlusive disease between patients receiving clofarabine vs fludarabine.n day 0 and day+90/100

    Comparison of occurrence of veno-occlusive disease : (Mohty et al, BMT 2016) betwee

    Time frame: day+90

  23. Safety assessment

    Safety assessment: the safety assessment shall be done by collecting all adverse events that occur during the research. All adverse event (except GvHD) shall be graded according to CTC-AE Toxicity Grading Scale (version 5).

    Time frame: 2 years

07

Study locations

20 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2028, 60 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 60 months is close to that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Jun 23, 2023
StartActual
Sep 14, 2023
Primary completionEst.
Sep 14, 2028
CompletionEst.
Sep 14, 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05917405
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Sep 14, 2023
Primary completion
Sep 14, 2028 (estimated)
Completion
Sep 14, 2028 (estimated)
Last update
Jan 30, 2026

Study contacts

Patrice CHEVALLIER, Pr
Contact
patrice.chevallier@chu-nantes.fr
MARION GAUTIER
Contact
marion.gautier@chu-nantes.fr
+33253526204
patrice CHEVALLIER, Pr
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clofarabine

Start the discussion